ArticleFrontiers in oncology2026
Trends and disparities in bone cancer mortality among US adults from 1999 to 2020: a joinpoint regression analysis based on the CDC WONDER database.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to describe trends in bone cancer-related mortality from 1999 to 2020 and analyze disparities across various demographic subgroups. Methods: Data were obtained from the CDC WONDER multiple cause of death database (1999-2020). Deaths of individuals aged 25 years or older with primary malignant bone cancer (ICD-10 codes C40-C41) as the underlying cause were included. AAMRs were calculated. Joinpoint regression analysis was employed to evaluate temporal trends and estimate the APC and AAPC. Results: From 1999 to 2020, a total of 25,859 bone cancer deaths were reported among US adults. The overall ASMR increased from 0.528 per 100,000 (95% CI: 0.495-0.562) in 1999 to 0.599 per 100,000 (95% CI: 0.569-0.682) in 2020, with an AAPC of 0.509 (95% CI: 0.196 to 0.931; p = 0.002) over the 22-year period. Joinpoint analysis identified three distinct segments: a non-significant decrease from 1999 to 2014 (APC = -0.218, p = 0.288), a significant increase from 2014 to 2018 (APC = 4.479, p = 0.157), and a non-significant decrease from 2018 to 2020 (APC = -1.779, p = 0.424). Mortality rates were higher in males (0.712 per 100,000) than in females (0.446 per 100,000). Adults aged 85 years and older had the highest mortality rate (3.430 per 100,000). Black or African American individuals experienced a higher mortality rate (0.584 per 100,000) compared to White (0.561 per 100,000) and Hispanic or Latino (0.335 per 100,000) individuals. Geographically, the South had the highest mortality rate (0.614 per 100,000), while the Northeast had the lowest (0.444 per 100,000). Conclusion: Bone cancer mortality among US adults showed an overall increasing trend from 1999 to 2020, with significant disparities by age, sex, race, and geographic region. The triphasic mortality trend may reflect evolving diagnostic technologies, treatment approaches, and healthcare accessibility. These findings provide valuable insights for public health planning and resource allocation aimed at reducing the burden of bone malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.